Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance.
Philip C. Mack
Consultant or Advisory Role - Boehringer Ingelheim; MolecularMD
Honoraria - Boehringer Ingelheim
Neal Goodwin
No relevant relationships to disclose
William S. Holland
No relevant relationships to disclose
Karen Kelly
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI
David R. Gandara
No relevant relationships to disclose